ESC-CHF: guidelines for the aspirational and the practical

被引：19

作者：

Brady, AJB ^{[1
]}

Poole-Wilson, PA

机构：

[1] Glasgow Royal Infirm, Dept Med Cardiol, Glasgow G4 0SF, Lanark, Scotland

[2] Natl Heart & Lung Inst, London, England

来源：

HEART | 2006年 / 92卷 / 04期

关键词：

D O I：

10.1136/hrt.2005.083980

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：437 / 440

页数：4

共 21 条

[11]

Fox KM, 2003, LANCET, V362, P782

[12]

Gerstein HC, 2000, LANCET, V355, P253

[13] Rates of hyperkalemia after publication of the randomized aldactone evaluation study [J].

Juurlink, DN ;

Mamdani, MM ;

Lee, DS ;

Kopp, A ;

Austin, PC ;

Laupacis, A ;

Redelmeier, DA .

NEW ENGLAND JOURNAL OF MEDICINE, 2004, 351 (06) :543-551

[14]

National Institute of Clinical Excellence (NICE), 2003, CHRON HEART FAIL MAN

[15] Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both [J].

Pfeffer, MA ;

McMurray, JJV ;

Velazquez, EJ ;

Rouleau, JL ;

Kober, L ;

Maggioni, AP ;

Solomon, SD ;

Swedberg, K ;

Van de Werf, F ;

White, H ;

Leimberger, JD ;

Henis, M ;

Edwards, S ;

Zelenkofske, S ;

Sellers, MA ;

Califf, RM ;

Aylward, P ;

Armstrong, P ;

Barvik, S ;

Belenkov, Y ;

Dalby, A ;

Diaz, R ;

Drexler, H ;

Ertl, G ;

Francis, G ;

Hampton, J ;

Harsanyi, A ;

Kvasnicka, J ;

Mareev, V ;

Marin-Neto, J ;

Murin, J ;

Myers, M ;

Nordlander, R ;

Opolski, G ;

Soler-Soler, J ;

Spac, J ;

Stefenelli, T ;

Sugrue, D ;

Van Gilst, W ;

Varshavsky, S ;

Weaver, D ;

Zannad, F ;

Aguilar, D ;

Alvarez, A ;

Al-Taweel, M ;

Anavekar, N ;

Finn, P ;

Lopez-Jimenez, F ;

Mercier, R ;

Lewis, E .

NEW ENGLAND JOURNAL OF MEDICINE, 2003, 349 (20) :1893-1906

[16] Effects of candesartan on mortality and morbidity in patients with chronic heart failure:: the CHARM-Overall programme [J].

Pfeffer, MA ;

Swedberg, K ;

Granger, CB ;

Held, P ;

McMurray, JJV ;

Michelson, EL ;

Olofsson, B ;

Östergren, J ;

Yusuf, S .

LANCET, 2003, 362 (9386) :759-766

[17] Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction [J].

Pitt, B ;

Remme, W ;

Zannad, F ;

Neaton, J ;

Martinez, F ;

Roniker, B ;

Bittman, R ;

Hurley, S ;

Kleiman, J ;

Gatlin, M .

NEW ENGLAND JOURNAL OF MEDICINE, 2003, 348 (14) :1309-1321

[18] The effect of spironolactone on morbidity and mortality in patients with severe heart failure [J].

Pitt, B ;

Zannad, F ;

Remme, WJ ;

Cody, R ;

Castaigne, A ;

Perez, A ;

Palensky, J ;

Wittes, J .

NEW ENGLAND JOURNAL OF MEDICINE, 1999, 341 (10) :709-717

[19] Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol, European Trial (COMET): randomised controlled trial [J].

Poole-Wilson, PA ;

Swedberg, K ;

Cleland, JGF ;

Di Lenarda, A ;

Hanrath, P ;

Komajda, M ;

Lubsen, J ;

Lutiger, E ;

Metra, M ;

Remme, WJ ;

Torp-Pedersen, C ;

Scherhag, A ;

Skene, A .

LANCET, 2003, 362 (9377) :7-13

[20]

*SIGN, 1999, DIAGN TREATM HEART F

← 1 2 3 →